Latest Safety News

Advanced Innergy Holdings Ltd (ASX, AIH) reported unaudited proforma FY25 results exceeding prospectus forecasts, driven by strong organic growth and the strategic acquisition of Ovun. The company reaffirms its FY26 guidance, supported by a robust orderbook and pipeline.

Theta Gold Mines reports steady progress on its TGME Gold Project with key civil works milestones achieved, keeping the project on schedule for commissioning by the end of 2026.

Critical Resources Limited has significantly expanded its Mavis Lake Lithium Project in Ontario, boosting its landholding by 25% and advancing exploration with promising high-grade lithium intercepts. The company also secured a strategic partnership to evaluate cutting-edge solid-state lithium-ion battery technology, positioning itself for the anticipated lithium market rebound.

Provaris Energy’s 2025 AGM highlights strategic progress in hydrogen and CO2 storage technologies, focusing on European market expansion and a refined licensing business model.

Element 25 Limited has announced significant progress in expanding its Butcherbird manganese mine and developing a US-based high-purity manganese refinery, backed by substantial government grants and strategic partnerships with automotive giants.

InhaleRx Limited has introduced SRX-25, an oral fixed-dose combination therapy targeting Treatment-Resistant Depression, aiming to improve patient access and adherence. The company also secured $1 million in capital to advance clinical development and plans a strategic rebrand.

Recce Pharmaceuticals has reported compelling preclinical results for its inhaled anti-infective RECCE 327, demonstrating potent activity against multidrug-resistant pneumonia bacteria in mice models.

Race Oncology has received ethics approval to launch its HARNESS-1 Phase 1a/b trial testing RC220 combined with osimertinib in EGFR-mutated non-small cell lung cancer patients, marking a key step toward addressing resistance to current therapies.

Patrys Limited has expanded its clinical pipeline by acquiring Reliis Pty Ltd, gaining a proprietary injectable formulation of Quetiapine aimed at the large and underserved delirium market. This strategic move balances Patrys’ portfolio with a near-term pharmaceutical asset alongside its biologics program.

Select Harvests Limited reported a robust FY2025 with a 32.4% almond price surge driving a $30.9 million NPAT increase and halving net debt. The company’s strategic investments and operational efficiencies position it well for a positive FY2026 outlook.

Select Harvests Limited delivered a robust FY2025 with net profit soaring to $31.8 million and net debt slashed by over 50%, despite a smaller almond crop. Strategic investments in processing and sales underpin a confident outlook.

Syntara Limited has successfully completed Phase 1a trials for its topical anti-fibrotic drug SNT-9465, demonstrating dose-dependent target engagement and safety, and is now progressing to an innovative Phase 1b study in hypertrophic scars.